FDA approval and four licensing deals anchor PharmTech roundup

Sophie Lindqvist

In its November 6, 2026 roundup, PharmTech reported that FDA granted accelerated approval to INOVIO’s VOCERYQ, a plasmid DNA immunotherapy and the agency’s first approved DNA medicine. The decision sets a precedent for nonviral plasmid products made by fermentation and puts drug-device combination controls at the center of commercial readiness.

What does the DNA approval change for CMC teams?

The milestone has clear planning consequences, but the roundup gives no patient count, comparator, endpoint, follow-up period, safety analysis, manufacturing yield, or device specification. It supports a regulatory and CMC milestone, not a comparative efficacy claim or cost forecast.

For R&D managers, the immediate work is to connect plasmid manufacturing, combination-device controls and commercial documentation rather than treat approval as a standalone research result. The source does not quantify the budget or schedule effect.

Which assets changed hands?

Four cross-border licensing deals announced during the week covered antibody-drug conjugates (ADCs), a molecular glue degrader and a gut-restricted agonist. PharmTech says each creates technology-transfer and scale-up demands for chemistry, manufacturing and controls teams.

• Boehringer Ingelheim and Sino Biopharmaceutical (SBP Group) signed an option and license agreement covering six preclinical ADC and T-cell engager programs.
• Nxera Pharma granted AbbVie exclusive worldwide rights to NXE0033744, an oral EP4 receptor agonist for inflammatory bowel disease.
• Minghui Pharmaceutical granted ASKA Pharmaceutical exclusive rights in Japan to MHB018A, a subcutaneous antibody targeting insulin-like growth factor 1 receptor (IGF-1R) for thyroid eye disease.
• Evommune in-licensed rights outside Greater China to EVO570, an oral molecular glue degrader from Hinova Pharmaceuticals.

The roundup lists no upfront payment, milestone schedule, royalty, manufacturing transfer plan or financing source for the agreements. Portfolio review therefore cannot rank the four transactions by expected value from this item alone; diligence must attach option-exercise criteria, CMC transfer milestones and trial-stage spending to each asset. The source does not state the development stage for the other three assets.

Where do laboratory workflows break down?

Reports from AAPS PharmSci 360 and CPHI Milan focused on impurity gaps, device mismatches and supply resilience. Veranova’s Subathra Ramamoorthy said forced degradation for potent APIs cannot be a checklist exercise: when teams handle OEB 4 and 5 compounds in tiny amounts inside isolators, carryover appears directly in results.

She advised sponsors to tell one consistent story for each impurity and to review filings as an agency reviewer would, because impurity deficiencies recur in submissions.

USP’s Catherine Sheehan and Tong (Jenny) Liu described tools under development to remove the novel-excipient bottleneck, including a weight-of-evidence safety approach and emerging standards. They urged manufacturers to engage early.

Almac Clinical Services’ Nishma Patel presented the CPHI Award-winning just-in-time Almac Adapt process, which delays packaging and labeling until each ultra-rare gene-therapy patient is confirmed ready. The aim is to protect scarce, irreplaceable doses.

Which operating decisions carry the most risk?

The expert commentary moved from assays to operating models and budget allocation. Its common test was whether teams could identify who owned each decision and prove that controls worked.

• Evocon’s Breandán Flood said continuous overall equipment effectiveness (OEE) monitoring can guide three capital choices: replace aging assets, retrofit them or leave them in service. That turns utilization and downtime data into replacement criteria rather than retrospective maintenance records.
• In a development article by Cynthia Challener, experts rejected the idea that one structural change can make peptides orally bioavailable. They called for joint optimization of stability, permeability, potency and manufacturability, which links assay work with process development.
• Partha S. Anbil and Anoop Sidharthan characterized most life-sciences data problems as ownership problems. Their proposed data mesh places responsibility for definitions and data quality with domain experts who publish the data.
• Brian Drapeau said the business case for regulated AI rests on cost per accepted outcome, not cost per generated output. He placed the burden in review, change control and quality-unit capacity, the functions that determine acceptance.
• In this month’s AI Pulse Check, Richard Jaenisch, Florin Muraru and Gourav Pandey warned that inspectors will assess companies against their own AI policies. They placed clear ownership, documented use and AI literacy ahead of deployment.

Why do drug shortages persist?

PharmTech Explained’s Zach Zubulake examined drug shortages through USP’s 2025 drug shortages report. USP’s Ronald Piervincenzi said the average shortage now lasts more than five years. He called the persistence an incentive problem: “the market doesn’t pay for reliability.”

The roundup does not give the report’s definition of a shortage, dataset, trend series or funding, so the five-year figure should guide questions about supplier qualification and contingency inventory, not serve as a stand-alone resilience model.

What can the evidence support?

PharmTech presents conference coverage, regulatory reporting, expert commentary and a regulatory-news index, not a controlled study. It supplies no sample sizes, comparative methods or funding attribution for the expert contributions, and it gives no clinical data for the licensed programs.

VOCERYQ’s approval is a reported regulatory milestone; the licensing announcements are transaction events; the impurity, AI and shortage statements are operational arguments or reported metrics, not new projections. PharmTech also refers readers to an October Regulatory Roundup for recent US and European actions without listing individual cases or dates.

Teams can still extract a practical sequence from the source: engage novel-excipient specialists early; build impurity narratives and reviewer-style checks into filings; reserve combination-device and CMC transfer capacity; and assign named owners for AI validation, data definitions and shortage escalation. Each step needs a budget line and acceptance criterion because the roundup provides no values for them.

The forward test is evidence before scale: VOCERYQ raises the bar for DNA-medicine readiness, while the six-program ADC deal, three other licenses and five-year shortage problem make CMC transfer, quality review and supply assurance portfolio issues rather than late-stage clean-up.